



吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

(於中華人民共和國註冊成立之股份有限公司)

(股份代號：8049)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2014

全年業績公佈 截至二零一四年十二月三十一日止年度

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “Directors”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited and its subsidiary (“the Group”). The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

香港聯合交易所有限公司(「聯交所」)創業板(「創業板」)之特色

創業板的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。創業板的較高風險及其他特色表示創業板較適合專業及其他老練投資者。

由於創業板上市公司新興的性質使然，在創業板買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險，同時無法保證在創業板買賣的證券會有高流通量的市場。

香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不會就本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。

本報告乃遵照聯交所《創業板證券上市規則》(「創業板上市規則」)提供有關吉林省輝南長龍生化藥業股份有限公司及其附屬公司(「本集團」)之資料，吉林省輝南長龍生化藥業股份有限公司各董事(「董事」)對本報告共同及個別承擔全部責任。董事在作出一切合理查詢後確認，就彼等所知及確信：(1)本報告所載資料在各主要方面均為準確及完整及無誤導成分；(2)並無遺漏任何其他事實，致令本報告之內容有所誤導；及(3)本報告所表達之意見乃經審慎周詳考慮後始行作出，並以公平合理之基準與假設為基礎。

CHAIRMAN'S STATEMENT

As the Chairman and on behalf of the Board of Directors (the "Board"), I am pleased to present the audited consolidated result of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the "Company") and its subsidiaries (collectively referred to as the "Group") for the year ended 31 December 2014.

During the year under review, the Group has spent significant efforts on further promoting its core products, namely Hai Kun Shen Xi capsule (海昆腎喜膠囊) and Compound Huonaoshu capsule (復方活腦舒膠囊). As a result, the total turnover of the Group for the year ended 31 December 2014 was RMB601,715,000, representing a sharp increase of 31% as compared with RMB457,746,000 for the previous year. Profit for the year attributable to owners of the Company increased to RMB132,785,000 from RMB79,274,000 last year. For the year ended 31 December 2014, basic earnings per share increased to RMB23.70 cents from RMB14.15 cents last year.

The notable achievements in 2014 were the results of joint effort of our staff at all levels. In fact, the Board of Directors has already expressed its optimistic view for 2014's profitability in the 2013 annual report. As such, the Board would like to share its view on the Company's competitive edges with shareholders since these edges would allow the Company to achieve further success in the coming years.

Firstly, basing on the sales growth of one single product, namely, the Hai Kun Shen Xi capsule (海昆腎喜膠囊) as our target; and through adapting innovative development as the guideline, academic promotion as the means, increase sales operation quality as the focus as well as ensuring clinical sales, we increased the sales of Compound Huonaoshu capsule (復方活腦舒膠囊). Meanwhile, we continued to make efforts on the production and marketing of injecting drugs, including Edaravone injection (依達拉奉注射液), and other products subject to business solicitation, and speed up the development of unexplored new markets to further improve our sales.

Secondly, we set aside a dedicated fund and actively organised and participated in various academic promotions in relation to nephrology at state level, and held specially designed product promotion meetings in targeted hospitals at provincial, city and district levels in the country, thereby achieving continued growth in product sales. At the same time, we communicated directly with frontline staffs through these activities so that we could carry out research and development more efficiently, and understand the market conditions better.

主席報告

本人謹代表董事會(「董事會」)欣然提呈吉林省輝南長龍生化藥業股份有限公司(「本公司」)及其附屬公司(合稱「本集團」)截至二零一四年十二月三十一日止年度之經審核綜合業績。

於回顧年度內，本集團致力提升對其核心產品的推廣，包括海昆腎喜膠囊和復方活腦舒膠囊。因此，截至二零一四年十二月三十一日止年度本集團總營業額為人民幣601,715,000元，較去年人民幣457,746,000元大幅上升31%。本年度本公司股權持有人應佔溢利由去年人民幣79,274,000元上升至約人民幣132,785,000元。截至二零一四年十二月三十一日止年度每股基本盈利由去年人民幣14.15分增加至人民幣23.70分。

二零一四年有突出之業績是全體員工共同努力的成果。事實上，董事會於二零一三年年報內已就二零一四年度之盈利能力發表了樂觀的看法。因此，董事會欣然與各股東分享本公司具有以下競爭力的優勢，該等優勢將為本公司以後之年度的發展再創新的輝煌。

首先，我們緊緊圍繞「海昆腎喜膠囊」單品種銷售量的增長目標，以創新發展為指導，以學術推廣為手段，以提高營銷質量為重點，抓好臨床上量，提升「復方活腦舒膠囊」銷量，繼續加大「依達拉奉注射液」等針劑品種和招商品種產銷力度，加快開發空白市場，使銷售業績再上一個新台階。

另一方面，我們拿出專項資金積極組織和參與國家級腎病學術推廣工作，在全國各省、市、區等目標醫院針對性開展產品推廣會議，推動產品銷量持續增長，通過這類活動可以直接與前線人員交流，在研發及瞭解市場情況方面取得了很好的效果。

Thirdly, our production lines, including No. One solid dosage capsule production workshop, No. Three solid dosage pills (concentrated pills) production workshop and the production line for bulk drug (fucoidan), had obtained the new version of Good Manufacturing Practice Certificate during the year. Meanwhile, we have made efforts in business solicitation for the solid dosage non-mainline products produced by the No. Three workshop and also in the tender of basic drug in order to diversify the development of the Company while exerting efforts in exploring and developing more mainline products.

Lastly, the Company passed the review of “national high-tech enterprise” in July 2012, and Hai Kun Shen Xi capsule (海昆腎喜膠囊) was named “Branded Products”.

Looking ahead, we will take the launch of our new plant as an opportunity to enhance our work on management and sales in every segment. We will adhere to our business philosophy, that is, focusing on “technological innovation and serving the public” in the course of globalization, and endeavour in the pursuit of health for people around the world, with the ultimate goal to achieve rapid growth and create a brighter future.

On behalf of the Board, I would like to express my heartfelt thanks to all levels of staff and the management for their efforts and contributions in 2014 and my deep gratitude to our clients, business partners and owners for their utmost support.

By order of the Board
Zhang Hong
Chairman

Jilin Province, the PRC
30 March 2015

再者，我們本年內固體制劑一車間硬膠囊劑生產線、固體制劑三車間丸劑(濃縮丸)生產線、褐藻多糖硫酸酯原料藥生產線全面通過了新版GMP認證，同時積極抓好固體制劑三車間小品種招商和基本藥物投標工作，促進企業多元化發展，努力開發和培育更多主導品種。

最後，公司於2012年7月通過了「國家高新技術企業」複審，海昆腎喜膠囊獲得「名牌產品」稱號。

展望未來，我們將以新廠區啟用為契機，促進各項管理及銷售工作的提升，秉承「科技、創新、厚德、濟世」的企業經營理念，把走全球化道路，為世界人類健康做貢獻作為公司發展的不懈努力和追求。全力打造一個快速騰飛的新長龍，鑄就更加輝煌的明天。

本人謹代表董事會對各級員工及管理層在二零一四年之努力工作和付出表示衷心感謝，對客戶，並業務夥伴及本公司股權持有人之鼎力支持致以深切謝意。

承董事會命
張弘
主席

中國吉林省
二零一五年三月三十日

ANNUAL RESULTS (AUDITED)

The Board of Directors (the "Board") of the Company are pleased to announce that the audited consolidated results of the Group for the year ended 31 December 2014, together with the comparative figures for the year ended 31 December 2013, as follow:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 December 2014
(Expressed in Renminbi)

年度業績(經審核)

本公司董事會(「董事會」)欣然公佈本集團截至二零一四年十二月三十一日止年度經審核綜合業績，連同截止二零一三年十二月三十一日止年度之比較數字如下：

綜合損益及其他全面收益表

截至二零一四年十二月三十一日止年度
(以人民幣列示)

			2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Turnover	營業額	3	601,715	457,746
Cost of sales	銷售成本		(115,213)	(84,689)
Gross profit	毛利		486,502	373,057
Other income	其他收入	5	11,309	14,768
Other gains	其他收益	6	7,000	109
Distribution and selling costs	分銷及銷售開支		(276,949)	(255,319)
Administrative expenses	行政開支		(67,901)	(37,347)
Profit from operations	經營溢利		159,961	95,268
Finance costs	融資成本	7	(297)	(659)
Profit before income tax	稅前溢利	8	159,664	94,609
Income tax expense	所得稅支出	9	(26,879)	(15,335)
Profit for the year	本年度溢利		132,785	79,274
Other comprehensive income	其他全面收益		-	-
Total comprehensive income for the year	本年度全面收益總額		132,785	79,274
Profit attributable to:	以下應佔溢利：			
Owners of the Company	本公司擁有人		132,785	79,274
Total comprehensive income attributable to:	以下應佔全面收益總額：			
Owners of the Company	本公司擁有人		132,785	79,274
Earnings per share	每股盈利			
- Basic (RMB cents)	- 基本(人民幣分)	10	23.70	14.15

CONSOLIDATED BALANCE SHEET

As at 31 December 2014
(Expressed in Renminbi)

綜合資產負債表

於二零一四年十二月三十一日
(以人民幣呈示)

			2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
	Notes 附註			
ASSETS AND LIABILITIES		資產及負債		
Non-current assets		非流動資產		
Bearer biological assets		不記名生物資產	5,169	4,890
Property, plant and equipment		物業、廠房及設備	144,307	99,483
Prepaid land lease payments		預付土地租金	16,882	17,335
Construction in progress		在建工程	66,781	145,834
Intangible assets		無形資產	2,519	11,229
			235,658	278,771
Current assets		流動資產		
Inventories		存貨	33,635	25,581
Trade receivables	11	應收貿易賬款	230,196	121,184
Other receivables, deposits and prepayments		其他應收款項、訂金及 預付款項	88,408	87,184
Loans receivables		應收貸款	35,000	36,590
Prepaid land lease payments		預付土地租金	453	454
Available-for-sale financial assets		可供出售財務資產	30,000	30,000
Cash and cash equivalents		現金及現金等值物	130,316	70,359
			548,008	371,352
Current liabilities		流動負債		
Trade payables	12	應付貿易賬款	13,559	10,830
Other payables, deposits received and accruals		其他應付款項、已收 訂金及應計費用	105,348	123,929
Deferred income		遞延收入	3,086	1,886
Income tax payable		應付所得稅	12,255	3,935
Other tax payables		其他應付稅項	13,847	8,326
Loans from government authority		政府機關貸款	1,317	682
Dividend payable		應付股息	1,827	1,873
			151,239	151,461
Net current assets		流動資產淨值	396,769	219,891
Total assets less current liabilities		總資產減流動負債	632,427	498,662

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Non-current liabilities	非流動負債		
Loans from government authority	政府機關貸款	3,513	4,148
Bank borrowings	銀行借貸	4,000	4,000
Deferred income	遞延收入	18,358	16,644
Deferred tax liabilities	遞延稅項負債	239	338
		26,110	25,130
Net assets	資產淨值	606,317	473,532
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY	本公司擁有人應佔 權益		
Share capital	股本	56,025	56,025
Reserves	儲備	550,292	417,507
Total equity	權益總額	606,317	473,532

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2014
(Expressed in Renminbi)

綜合權益變動表

截至二零一四年十二月三十一日止年度
(以人民幣呈示)

		Share capital 股本 RMB'000 人民幣千元	Share premium 股份溢價 RMB'000 人民幣千元	Statutory surplus reserve 法定盈餘儲備 RMB'000 人民幣千元	Retained profits 保留溢利 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
Balance at 1 January 2013	於二零一三年一月一日之結餘	56,025	51,098	33,242	253,893	394,258
Comprehensive income	全面收益					
Profit for the year	本年度溢利	-	-	-	79,274	79,274
Other comprehensive income	其他全面收益	-	-	-	-	-
Total comprehensive income	全面收益總額	-	-	-	79,274	79,274
Transactions with owners	股東之交易					
Appropriation to statutory surplus reserve	撥款至法定盈餘儲備	-	-	-	-	-
At 31 December 2013	於二零一三年十二月三十一日	56,025	51,098	33,242	333,167	473,532
Balance at 1 January 2014	於二零一四年一月一日之結餘	56,025	51,098	33,242	333,167	473,532
Comprehensive income	全面收益					
Profit for the year	本年度溢利	-	-	-	132,785	132,785
Other comprehensive income	其他全面收益	-	-	-	-	-
Total comprehensive income	全面收益總額	-	-	-	132,785	132,785
Transactions with owners	股東之交易					
Appropriation to statutory surplus reserve	撥款至法定盈餘儲備	-	-	-	-	-
At 31 December 2014	於二零一四年十二月三十一日	56,025	51,098	33,242	465,952	606,317

1. GENERAL INFORMATION

The Company was established as a state-owned enterprise in the People's Republic of China (the "PRC") in 1989. On 29 December 1995, under the relevant provisions of the Company Law of the PRC, the Company was re-organised from a state-owned enterprise to a limited liability company. On 16 August 1996, with the approval of the Economic Restructuring Commission of Jilin Province, the Company was further converted into a joint stock limited company. On 20 April 1999, the Company made a bonus issue from capitalisation of retained profits in the proportion of one bonus share for every two existing shares.

The Company's H shares are listed on the Growth Enterprise Market ("GEM") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 24 May 2001.

The Company is principally engaged in the manufacture and distribution of biochemical medicines in the PRC under the brand names of Changlong and Shendi.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") which collective term includes all applicable individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and Interpretation issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong, applicable disclosure provisions of the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules") and requirements of the Hong Kong Companies Ordinance, which for this financial year and the comparative period continue to be those of the predecessor Hong Kong Companies Ordinance (Cap.32), in accordance with transitional and saving arrangements for Part 9 of the new Hong Kong Companies Ordinance (Cap.622), "Accounts and Audit", which are set out in sections 76 to 87 of Schedule 11 to that Ordinance.

1. 一般資料

本公司於一九八九年在中華人民共和國(「中國」)成立為一間國有企業。一九九五年十二月二十九日，根據中國公司法有關條文，本公司由一間國有企業重組為一間有限責任公司。其後於一九九六年八月十六日，經吉林省經濟改革委員會的批准，本公司再改組為一間股份有限公司。於一九九九年四月二十日，本公司按每兩股現有股份派發一股紅股的比例，將保留溢利撥充資本以發行紅股。

本公司H股於二零零一年五月二十四日在香港聯合交易所有限公司(「聯交所」)創業板(「創業板」)上市。

本公司主要以長龍及神迪品牌在中國從事製造及分銷生化藥物。

2. 重大會計政策概要

編製該等綜合財務報表所採納之會計政策載於下文。除另有指明外，該等政策乃貫徹應用於所呈報之年度。

(a) 遵例聲明

本綜合財務報表乃按照香港會計師公會(「香港會計師公會」)頒佈的香港財務報告準則(「香港財務報告準則」，此統稱包括所有適用之個別香港財務報告準則、香港會計準則(「香港會計準則」)及其詮釋)、香港普遍採納的會計原則、香港聯合交易所有限公司創業板證券上市規則(「創業板上市規則」)適用的披露條文及香港《公司條例》之規定而編製(根據香港法例第622章新香港《公司條例》附表11第76至87條所載第9部「賬目及審計」的過渡性及保留安排，就本財政年度及比較期間繼續使用前香港《公司條例》(第32章)規定的適用披露)。

(b) Basis of preparation

The consolidated financial statements have been prepared under the historical cost convention, as modified by certain biological assets and available-for-sale financial assets measured at fair value.

The preparation of financial statements in conformity with HKFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies.

(c) Changes in accounting policy and disclosures

In the current year, the Group has applied the following new and revised Standards, Amendments and Interpretations ("new and revised HKFRSs") issued by the HKICPA that are effective for accounting periods beginning on or after 1 January 2014.

HKFRS 10, HKFRS 12 and HKAS 27 (Amendments)	Investment entities
HKAS 32 (Amendments)	Offsetting financial assets and financial liabilities
HKAS 36 (Amendments)	Recoverable amount disclosures for non-financial assets
HKAS 39 (Amendments)	Novation of derivatives and continuation of hedge accounting
HK(IFRIC) – INT 21	Levies

The application of the new and revised HKFRSs in the current year has had no material impact on the Group's financial performance and positions for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

(b) 編製基準

本綜合財務報表已按歷史成本法慣例編製，並以公平值計量之若干生物資產和可供出售財務資產作出修訂。

根據香港財務報告準則編製財務報表須運用若干關鍵會計估計，而管理層於應用本集團會計政策亦須作出判斷。

(c) 會計政策及披露之變更

於本年度，本集團已應用以下由香港會計師公會頒佈並對二零一四年一月一日或其後開始的會計期間生效的新訂及經修訂準則、修訂及詮釋（「新訂及經修訂香港財務報告準則」）。

香港財務報告準則第10號、 香港財務報告準則第12號及 香港會計準則第27號 (修訂本)	投資實體
香港會計準則第32號 (修訂本)	抵銷金融資產及金融負債
香港會計準則第36號 (修訂本)	非金融資產之可收回金額 披露
香港會計準則第39號 (修訂本)	衍生工具之更替及對沖 會計之延續
香港(國際財務報告詮釋 委員會) – 詮釋第21號	徵費

於本年度應用新訂及經修訂香港財務報告準則對本集團於本年度及過往年度之財務表現及狀況及／或於該等綜合財務報表內載列之披露並無重大影響。

New standards, amendments to standards and interpretations

The Group has not early applied the following new and revised HKFRSs that have been issued but are not yet effective.

HKFRS 9	Financial instruments ⁴
HKFRS 14	Regulatory deferral accounts ²
HKFRS 15	Revenue from contracts with customers ³
HKFRS 11 (Amendments)	Accounting for acquisitions of interests in joint operations ²
HKAS 16 and HKAS 38 (Amendments)	Clarification of acceptable methods of depreciation and amortisation ²
HKAS 16 and HKAS 41 (Amendments)	Agriculture: Bearer plants ²
HKAS 19 (Amendments)	Defined benefit plans: Employee contributions ¹
HKAS 27 (Amendments)	Equity method in separate financial statements ²
HKFRS 10 and HKAS 28 (Amendments)	Sale and contribution of assets between an investor and its associate or joint venture ²
HKFRSs (Amendments)	Annual improvements HKFRSs 2010 – 2012 cycle ¹
HKFRSs (Amendments)	Annual improvements HKFRSs 2011 – 2013 cycle ¹
HKFRSs (Amendments)	Annual improvements HKFRSs 2012 – 2014 cycle ²

(1) Effective for annual periods beginning on or after 1 July 2014.

(2) Effective for annual periods beginning on or after 1 January 2016.

(3) Effective for annual periods beginning on or after 1 January 2017.

(4) Effective for annual periods beginning on or after 1 January 2018.

The Group did not early adopt any of these new or revised HKASs and HKFRSs, amendments and interpretation to existing HKASs and HKFRSs. Management is currently assessing the financial impact of these revisions to the Group's financial position and performance.

In addition, the Hong Kong Companies Ordinance (Cap. 622) will affect the presentation and disclosure of certain information in the consolidated financial statements for the year ending 31 December 2015. The Group is in the process of making an assessment of the impact of these changes.

新訂準則、準則修訂及詮釋

本集團並無提前應用下列已頒佈但尚未生效的新訂及經修訂的香港財務報告準則。

香港財務報告準則第9號	金融工具 ⁴
香港財務報告準則第14號	監管遞延賬目 ²
香港財務報告準則第15號	客戶合約收益 ³
香港財務報告準則第11號 (修訂本)	收購合營業務權益之會計法 ²
香港會計準則第16號及 香港會計準則第38號(修訂本)	可接受之折舊及攤銷方法之分類 ²
香港會計準則第16號及 香港會計準則第41號(修訂本)	農業：生產性植物 ²
香港會計準則第19號(修訂本)	定額福利計劃：僱員供款 ¹
香港會計準則第27號(修訂本)	獨立財務報表之權益法 ²
香港財務報告準則第10號及 香港會計準則第28號 (修訂本)	投資者與其聯營公司及合營公司之間 之資產出售及注資 ²
香港財務報告準則(修訂本)	香港財務報告準則二零一零年至 二零一二年週期之年度改進 ¹
香港財務報告準則(修訂本)	香港財務報告準則二零一一年至 二零一三年週期之年度改進 ¹
香港財務報告準則(修訂本)	香港財務報告準則二零一二年至 二零一四年週期之年度改進 ²

(1) 於二零一四年七月一日或之後開始之年度期間生效。

(2) 於二零一六年一月一日或之後開始之年度期間生效。

(3) 於二零一七年一月一日或之後開始之年度期間生效。

(4) 於二零一八年一月一日或之後開始之年度期間生效。

本集團並無提早採納任何此等新訂或經修訂香港會計準則及香港財務報告準則、對現有香港會計準則及香港財務報告準則之修訂及詮釋。管理層目前正在評估該等修訂對本集團財務狀況及表現之影響。

此外，香港《公司條例》(第622章)將影響截至二零一五年十二月三十一日止年度綜合財務報表內若干資料之呈列及披露。本集團正評估此等變動的影響。

3. TURNOVER

The principal activities of the Group are manufacture and distribution of biochemical medicines. Revenue represents the invoiced value of merchandise sold less allowances for returns, discounts, value-added tax and other sales related taxes.

3. 營業額

本集團之主要業務是製造及分銷生化藥物。收入指銷售商品的發票值，並已減去有關退貨、折扣、增值稅及其他銷售相關稅項的金額。

	2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Sales of medicine	601,715	457,746

4. SEGMENT INFORMATION

Segment information

Information reported to the Executive Directors of the Company, being the chief operating decision-makers ("CODM"), for the purpose of resource allocation and assessment of segment performance focuses on type of goods delivered.

The executive directors have identified that, the Group has only one reportable operating segment, which is the manufacture and distribution of biochemical medicines in the PRC. Since this is the only reportable operating segment of the Group, no further operating segment analysis thereof is presented.

Geographical information

In addition, the Group's revenue, expenses, results, assets and liabilities and capital expenditures are predominantly attributable to a single geographical region, which is the PRC. Therefore, no analysis by geographical regions is presented.

Information about major customers

There is no revenue from customers for the years ended 31 December 2014 and 2013 contributed over 10% of the total operating revenue of the Group.

4. 分類資料

分部資料

集團向執行董事，即主要經營決策人，就資源分配及評核分類表現而呈報之分類資料，乃按營運單位所交付的貨物種類作為分析基準。

執行董事已識別本集團僅有一個可呈報經營分部，而該唯一分部為於中國製造和分銷生化藥物。因此，並無呈報其進一步經營分部分析。

地區資料

此外，本集團的收入、開支、業績、資產及負債以及資本開支絕大部份來自單一地區，即中國。因此，並無呈報地區分析。

有關主要客戶之資料

截至二零一四年及二零一三年十二月三十一日止年度，並無來自客戶之收益佔本集團總營運收益超過10%。

5. OTHER INCOME

5. 其他收入

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Recovery of bad debts previously written off	收回已撇銷壞賬	115	351
Bank interest income	銀行利息收入	491	497
Government subsidies (Note)	政府補貼(附註)	1,593	5,760
Recognition of deferred income	確認遞延收入	3,086	1,886
Interest income on loans receivables	應收貸款利息收入	2,815	2,899
Yield gain on available-for-sale financial assets	可供出售財務資產回報收益	662	261
Reversal of impairment of inventories	存貨減值回撥	1,061	-
Reversal of provision of trade receivables	應收貿易賬款撥備回撥	568	-
Reversal of provision of other receivables	其他應收款撥備回撥	-	1,629
Reversal of provision of deposit and prepayment	訂金及預付款項撥備回撥	-	989
Others	其他	918	496
		11,309	14,768

Note: During the year ended 31 December 2014 and 2013, the Group received subsidies from various local municipal government bodies in the PRC, which aimed at the general financing of the business and technology development of the Group.

附註：於截至二零一四年及二零一三年十二月三十一日止年度，本集團獲得中國不同地方市政府機關的資助，旨在為本集團的業務及技術發展提供一般性資金。

6. OTHER GAINS

6. 其他收益

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Gain on disposal of property, plant and equipment	出售物業、廠房及設備盈利	-	109
Gain on disposal of intangible assets	出售無形資產盈利	7,000	-
		7,000	109

7. FINANCE COSTS

7. 融資成本

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Interest expenses on loans from government authority	政府機關貸款之利息費用	177	179
Interest expenses on short-term bank borrowings, unsecured	無抵押，短期銀行借貸之利息費用	-	360
Interest expenses on long-term bank borrowings, wholly repayable within five years, unsecured	無抵押，於五年內償還長期銀行借貸之利息費用	120	120
		297	659

8. PROFIT BEFORE INCOME TAX

8. 稅前溢利

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Profit before income tax for the year is arrived at after charging/(crediting):–	本年稅前溢利 已扣除／(計入) 下列各項：–		
Cost of inventories sold (excluding additional provision for, and write off of obsolete and slow-moving inventories)	已出售存貨成本(不包括增加撥備及撇銷廢棄及滯銷存貨)	106,580	77,933
Provision for obsolete and slow-moving inventories	廢棄及滯銷存貨撥備	–	2,699
Impairment loss on intangible assets	無形資產減值虧損	6,085	–
Impairment loss on loans receivables	應收貸款之減值虧損	12,090	2,513
Impairment loss on trade receivables	應收貿易賬款之減值虧損	–	678
Impairment loss on other receivables, deposit and prepayment	其他應收款、訂金及預付款項之減值虧損	1,886	–
Impairment loss on property, plant and equipment	物業、廠房及設備減值虧損	8,497	1,457
Auditor's remuneration:–	核數師酬金：–		
Provision for the year	年內撥備	210	268
Over-provision in prior years	過往年度超額撥備	(9)	–
Amortisation of intangible assets (included in cost of sales)	無形資產攤銷(列入銷售成本)	3,815	4,626
Research and development cost	研發費用	1,364	3,685
Amortisation of prepaid land lease payments (included in cost of sales)	預付土地租金攤銷(列入銷售成本)	454	453
Depreciation of property, plant and equipment	物業、廠房及設備折舊	11,489	8,601
Employee benefits expenses (excluding directors' and supervisors' remuneration):	員工福利費用(不包括董事及監事酬金)：		
Salaries and allowances	薪金及津貼	142,073	122,234
Pension scheme contributions	退休金計劃供款	1,576	1,120
Loss/(gain) on disposal of property, plant and equipment	出售物業、廠房及設備虧損／(盈利)	10,747	(109)

9. INCOME TAX EXPENSE

(a) Income tax represents:

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
PRC enterprise income tax	中國企業所得稅		
– Current year	– 本年度	28,246	15,058
– Overprovision in prior years	– 過往年度超額撥備	(1,268)	–
Deferred taxation	遞延稅項	(99)	277
		26,879	15,335

The PRC enterprise income tax is provided according to the relevant laws and regulations in the PRC.

On 16 March 2007, the National People's Congress approved the PRC Enterprise Income Tax Law, which became effective from 1 January 2008. In accordance with the new tax law, a unified enterprise income tax rate of 25% is applied to both domestic-invested enterprises and foreign-invested enterprises.

On 12 March 2012, the Company was accredited as a "National New and High-tech Enterprise" by the Jilin Provincial Science and Technology Bureau (吉林省科學技術廳) and is entitled to a reduced PRC Enterprise Income tax rate of 15% for the three consecutive years commenced since year 2012.

中國企業所得稅乃根據中國有關法律及法規撥備。

於二零零七年三月十六日，全國人大會議批准中國企業所得稅法，由二零零八年一月一日起生效。根據新稅法，所有內資及外資企業按統一稅率25%繳納企業所得稅。

本公司於二零一二年三月十二日獲吉林省科學技術廳譽為國家高新企業。本公司於二零一二年起計連續三年可按減免中國企業所得稅率至15%繳納稅項。

(b) Reconciliation between tax expense and accounting profit at applicable tax rate:

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Profit before income tax	稅前溢利	159,664	94,609
National tax calculated at PRC enterprise income tax rate of 15% (2013: 15%)	按中國企業所得稅率15% (二零一三年：15%) 計算的國稅	23,950	14,191
Tax effect of non-deductible expenses	不可扣稅開支的稅務影響	4,296	867
Overprovision in prior years	過往年度超額撥備	(1,268)	–
Deferred tax on temporary differences in prior year	過往年度暫時差額之遞延稅項	(99)	277
Income tax expense	所得稅支出	26,879	15,335

(b) 稅項支出與會計溢利按適用稅率對賬如下：

10. EARNINGS PER SHARE

The calculation of basic earnings per share for the year ended 31 December 2014 is based on the profit attributable to owners of the Group for the year of RMB132,785,000 (2013: RMB79,274,000) and 560,250,000 shares in issue during the year (2013: 560,250,000 shares).

Diluted earnings per share is not presented as there were no dilutive potential ordinary shares in existence during the years ended 31 December 2014 and 2013.

11. TRADE RECEIVABLES

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Trade receivables	應收貿易賬款	238,278	129,834
Less: Provision for impairment	減：減值撥備	(8,082)	(8,650)
Trade receivables – net	應收貿易賬款－淨額	230,196	121,184

- (i) The Group's policy is to allow an average credit period of 180 days to its trade customers.
- (ii) The movements in the provision for impairment for doubtful debts during the year, including both specific and collective loss components, are as follows:

- (i) 本集團政策為給予貿易客戶平均180日之信貸期。
- (ii) 年內呆賬減值撥備的變動(包括特定及集體虧損部分)如下：

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
At 1 January	於一月一日	8,650	7,972
Additional provision	增加撥備	-	678
Reversal	回撥	(568)	-
At 31 December	於十二月三十一日	8,082	8,650

Provision for doubtful debts had been made for the estimated irrecoverable amounts arising from the sale of goods. The provision was determined by the directors with reference to past default experience.

呆賬撥備乃就出售貨物之估計不可收回金額作出。董事已參考過往拖欠經驗釐定有關撥備金額。

10. 每股盈利

截至二零一四年十二月三十一日止年度，每股基本盈利乃根據年內本集團擁有人應佔溢利人民幣132,785,000元(二零一三年：人民幣79,274,000元)及年內已發行股份560,250,000股(二零一三年：560,250,000股)計算。

由於截至二零一四年及二零一三年十二月三十一日止兩個年度並無潛在攤薄普通股，故並無呈列每股攤薄盈利。

11. 應收貿易賬款

(iii) The ageing analysis of trade receivables, based on the invoice date and net of provision for impairment of trade receivables, is as follows:

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Current	即期	60,334	38,299
31-90 days	31-90日	111,595	39,767
91-180 days	91-180日	35,068	22,023
More than 180 days	超過180日	23,199	21,095
		230,196	121,184

(iii) 根據發票日期及扣除應收貿易賬款減值撥備，應收貿易賬款的賬齡分析如下：

(iv) The ageing analysis of trade receivables that are neither individually nor collectively considered to be impaired is as follows:

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Neither past due nor impaired	並無逾期或減值	206,997	100,089
Less than 1 month past due	逾期少於一個月	8,474	5,233
1 to 3 months past due	逾期一至三個月	7,768	4,706
Over 3 months past due	逾期超過三個月	7,296	4,430
		230,535	114,458

(iv) 並無個別或集體視作減值的應收貿易賬款賬齡分析如下：

Trade receivables that were neither past due nor impaired relate to a wide range of customers for whom there was no recent history of default.

概無逾期或減值的應收貿易賬款與眾多並無近期欠款記錄之客戶有關。

Trade receivables that were past due but not impaired relate to a number of independent customers that have a good track record with the Group. Based on past experience, management believes that no impairment is necessary in respect of these balances as there has not been a significant change in credit quality and the balances are still considered fully recoverable. The Group does not hold any collateral over these balances.

逾期但無減值的應收貿易賬款與多名獨立客戶有關，該等客戶對本集團的信貸記錄良好。根據過往經驗，管理層認為，該等結餘毋須減值，原因為信貸質素並無重大變動，且結餘仍被視作可全數收回。本集團並無就該等結餘持有抵押品。

(v) The Directors consider the carrying amount of trade receivables approximates their fair value.

(v) 董事認為，應收貿易賬款之賬面值與其公平值相若。

12. TRADE PAYABLES

The ageing analysis of trade payables, based on the invoice date, is as follows:

		2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Current	即期	4,339	3,015
31-90 days	31-90日	2,702	1,797
Over 90 days	超過90日	6,518	6,018
		13,559	10,830

The average credit period from the Group's and the Company's trade creditors is 90 to 180 days.

Trade payables principally comprise amounts outstanding for trade purchases. The directors consider the carrying amount of trade payables approximates their fair value.

12. 應付貿易賬款

以下為基於發票日期的應付貿易賬款的賬齡分析：

	2014 二零一四年 RMB'000 人民幣千元	2013 二零一三年 RMB'000 人民幣千元
Current	4,339	3,015
31-90 days	2,702	1,797
Over 90 days	6,518	6,018
	13,559	10,830

本集團及本公司貿易債權人之平均信貸期為90日至180日。

應付貿易賬款主要包括未償還購貨金額。董事認為應付貿易賬款之賬面值與其公平值相若。

MANAGEMENT DISCUSSION AND ANALYSIS BUSINESS REVIEW

For the year ended 31 December 2014, the Group's turnover increased to RMB601,715,000 from approximately RMB457,746,000 while the profit for the year attributable to owners of the Company increased to RMB132,785,000 from RMB79,274,000. For the year ended 31 December 2014, basic earnings per share increased to RMB23.70 cents from RMB14.15 cents last year.

For the year ended 31 December 2014, the manufacturing and sales of Hai Kun Shen Xi capsule (海昆腎喜膠囊) continued to be the Group's core source of revenue. The medicine of Hai Kun Shen Xi capsule has penetrated into the market, the sales of 2014 rose as expected, details of which were further elaborated under the Section "Financial Review".

OPERATION REVIEW

Good Manufacturing Practice (GMP)

During the year ended 31 December 2014, the Company has already obtained GMP certificates for the following:

1. Tablets (片劑) – valid until 8 August 2015
2. Capsules (硬膠囊劑) – valid until 8 August 2015
3. Sterile Bulk (Cefalotin sodium, Cefpiramide) (無菌原料藥(頭孢噻吩鈉、頭孢匹胺)) – valid until 8 August 2015
4. Pills (Water Pills), Membrane (丸劑(水丸)、膜劑) – valid until 8 August 2015
5. Powder for injection (Cephalosporins) (頭孢菌素類粉針劑) – valid until 29 December 2018
6. Lyophilized powder for injection (凍乾粉針劑) – valid until 29 December 2018
7. Small volume Parenteral Solution (小容量注射劑) – valid until 29 December 2018
8. Sterile Bulk (Yan Suan Tou Bao Jia Tong) (無菌原料藥(鹽酸頭孢甲肟)), Bulk (Edaravone) (原料藥(依達拉奉)) – valid until 17 October 2018
9. Bulk drug (Fucoidan, Extractum for fructus gardeniae) 原料藥(褐藻多糖酸酯、梔子提取物) – valid unit 31 December 2015

管理層討論與分析 業務回顧

截至二零一四年十二月三十一日止年度，本集團營業額由約人民幣457,746,000元增加至人民幣601,715,000元。本年度本公司股權持有人應佔溢利由人民幣79,274,000元增加至人民幣132,785,000元。截至二零一四年十二月三十一日止年度，每股基本盈利由去年之人民幣14.15分上漲至人民幣23.70分。

截至二零一四年十二月三十一日止年度，「海昆腎喜膠囊」的生產及銷售繼續為本集團的核心收入來源。海昆腎喜膠囊已滲入市場，於二零一四年銷售額達到預期的增長，詳情於「財務回顧」一節中闡述。

營運回顧

「優良製造標準」認證(GMP)

截至二零一四年十二月三十一日止年度，本公司已於下列劑型獲得GMP認證：

1. 片劑—有效至二零一五年八月八日
2. 硬膠囊劑—有效至二零一五年八月八日
3. 無菌原料藥(頭孢噻吩鈉、頭孢匹胺)—有效至二零一五年八月八日
4. 丸劑(水丸)、膜劑—有效至二零一五年八月八日
5. 頭孢菌素類粉針劑—有效至二零一八年十二月二十九日
6. 凍乾粉針劑—有效至二零一八年十二月二十九日
7. 小容量注射劑—有效至二零一八年十二月二十九日
8. 無菌原料藥(鹽酸頭孢甲肟)，原料藥(依達拉奉)—有效至二零一八年十月十七日
9. 原料藥(褐藻多糖酸酯、梔子提取物)—有效至二零一五年十二月三十一日

RESEARCH AND DEVELOPMENT

The Research and Development (R&D) department is essential for the future success of a pharmaceutical company. In the past, our R&D department had successfully developed the medicine, Compound Huonaoshu capsule, which had generated huge profit to the Company and finally led to the listing of the Company in Hong Kong. In the year of 2003, our R&D department completed the development of Hai Kun Shen Xi capsule, which has now become the first largest contributor of revenue and its revenue rose as expected.

PRODUCTION FACILITIES

In 2013, the addition of the construction in progress included acquisition of a plot of land of approximately 50,000 sq.m., which will be the third phase of our new production line developments, while the lands acquired in the year 2012 represented the first and second development phase.

The first and second development phase represented an area of approximately 12,000 sq.m., which houses six production lines and two workshops for producing five medicaments under two Good Manufacturing Practice Certificates; and an area of approximately 20,000 sq.m., which houses six production lines and three workshops for producing six medicaments under two Good Manufacturing Practice Certificates, respectively. The first development phase has been completed and in use since 2012, while the second phase has been completed in 2013 and commenced operation in February 2014. The third phase is currently under construction as we have completed the construction of a workshop and obtained the GMP certification in December 2014. With the official commencement of operation of the third phase at the middle of 2015, we believe the production capacity of the Group will be further enhanced.

FINANCIAL REVIEW

For the year ended 31 December 2014, the Group's recorded a revenue amounted to approximately RMB601,715,000 (2013: RMB457,746,000), a growth of approximately 31% as compared with the figure of the previous year. The audited profit for the year attributable to owners of the Company was approximately RMB132,785,000, representing an increase of 67% as compared with RMB79,274,000 of the previous year. The basic earnings per share amounted to RMB23.70 cents (2013: RMB14.15 cents), representing an increase of RMB9.55 cents over the previous year.

The obvious growth in turnover was mainly attributable to the increase in the revenue from our core revenue generator, namely Hai Kun Shen Xi capsule (海昆腎喜膠囊). The medicine of Hai Kun Shen Xi capsule had penetrated into the market, with the sales in 2014 rose as expected.

研究及開發

製藥公司之研發部對公司日後成功與否起重要之作用。以往，我們的研發部成功開發復方活腦舒膠囊，為本公司帶來龐大溢利，並最後促使本公司於香港上市。於二零零三年，我們的研發部完成開發海昆腎喜膠囊，現已成為我們第一大收入來源，來自該藥品的收入達到預期的增長。

生產設施

於二零一三年度新增的在建工程中包括新購置土地約5萬平方米，為本集團進行第三期生產線的發展；而於2012年新購置土地則為本集團第一期和第二期生產線的發展。

第一期和第二期生產線的發展分別為約1.2萬平方米的廠房，配置六條生產線和兩個車間，已獲得兩個GMP認證並可生產五個劑型；及約2萬平方米的廠房配置六條生產線和三個車間，已獲得兩個GMP認證並可生產六個劑型。第一期已完成並於二零一二年內投入生產，第二期於二零一三年度內完成並於二零一四年度二月開始運作，第三期仍在建造中，現已完成一個生產車間的建設，並於二零一四年度十二月獲得了GMP認證，於二零一五年年中可正式投入生產。我們相信本集團的生產能力將進一步提升。

財務回顧

截至二零一四年十二月三十一日止年度，本集團錄得收入較去年增長約31%，至約人民幣601,715,000元(二零一三年：人民幣457,746,000元)。本年度本公司股權持有人應佔經審核溢利較去年人民幣79,274,000元增長67%，達到約人民幣132,785,000元。每股基本盈利較去年增長人民幣9.55分至人民幣23.70分(二零一三年：人民幣14.15分)。

營業額大幅增加主要由於本集團核心收入來源的收入增加，即海昆腎喜膠囊。海昆腎喜膠囊已滲入市場，於二零一四年銷售額達到預期的增長。

The Board of Directors is pleased with the financial performance in 2014. It is believed that the remarkable growth in profitability is attributed to the following reasons.

Firstly, with its explicit therapeutic effects as well as pragmatic and innovative academic promotion, our dominant product, namely Hai Kun Shen Xi capsule (海昆腎喜膠囊), has become increasingly notable among similar drugs in the PRC in terms of its competitive strength and continuous expanding market, resulting in an increasing product sales. This together with the fact that our production lines, including No. One solid dosage capsule production workshop, No. Three solid dosage pills (concentrated pills) production workshop and production line for bulk drug (fucoidan), have obtained the new version of Good Manufacturing Practice Certificate in 2014, bolstered the growth and development of the Company.

Secondly, we strengthened our efforts on integrating market resources, encouraging reasonable mobility of personnel, unifying the price of products supplied and regulating sales practices. Focusing on enhancing clinical sales, efforts were made in various areas, such as soliciting business from the medicine departments of hospitals, in order to identify new profit drivers.

Thirdly, in addition to proactively organizing and participating in academic promotion in relation to nephrology at state level, we also focused on the annual activities held under the Academic Institute of Nephrology (腎病學術年會) and seminars on pharmaceutical products at provincial and prefecture levels. As the participants are clinical experts, we are in a better position to learn more about and expand the fundamental medical market through responding to patients' feedback more efficiency.

Fourthly, we enhanced our efforts to recruit new sales staffs and are dedicated to train sales teams in order to improve their overall quality and strengthen their capabilities. We have nurtured the sense of overall awareness and the sense of responsibilities among every salesperson in charge of regional markets and provincial sales managers. Meanwhile, we have also focused on getting our products covered by local medical insurance and included in the supplemental catalogue for the new rural cooperative medical system. We also put in efforts on product tender and filing of product prices. Through our concerted effort, we accelerated the development of markets and hence making our market coverage wider.

The gross profit margin for the year ended 31 December 2014 was approximately 80.9%, representing a 0.6% decrease as compared with that of 81.5% for the year ended 31 December 2013.

For the year ended 31 December 2014, the Group recorded other income and gains of approximately RMB18,309,000, contrasting to a figure of RMB14,877,000 for the year ended 31 December 2013.

董事會對二零一四年的財務業績表示滿意，董事會相信盈利能力的顯著增長乃歸功於以下幾點原因：

一是主導品種「海昆腎喜膠囊」因產品療效確切和學術推廣工作務實創新，在國內同類藥品中競爭優勢日益突出，市場開發面不斷擴展，產品銷量持續增長。二零一四年固體製劑一車間硬膠囊劑生產線、固體製劑三車間丸劑(濃縮丸)生產線、褐藻多糖硫酸酯原料藥生產線全面通過新版GMP認證，拉動了企業持續發展。

二是進一步加強市場資源整合，促進人員合理流動，統一供貨價格，規範銷售行為，圍繞臨床銷售增量開展各項工作，開發醫院拓展醫藥科室，尋找新的增長點。

三是積極組織和參與國家級腎病學術推廣工作，重點抓好區域的省、地級腎病學術年會活動和用藥科室的產品學術講座活動，省、地級腎病學術年會面對的都是臨床專家，能夠更好地學習和拓展基層醫療市場，回饋患者的評價。

四是加大招聘新銷售人員力度的基礎上，抓好銷售隊伍培訓工作，努力提高團隊綜合素質，增強團隊整體能力。各區域市場負責人和省級銷售經理亦加強大局意識，增強責任心，重點抓好產品進入地方醫保、新農合補充目錄、產品招投標和物價備案等基礎工作，從上而下團結一致，促使開發銷售市場的時間加快，版圖更遼闊。

截至二零一四年十二月三十一日止年度，邊際毛利約為80.9%，較截至二零一三年十二月三十一日止年度之81.5%減少0.6%。

截至二零一四年十二月三十一日止年度，本集團錄得其他收入及收益約人民幣18,309,000元，而截至二零一三年十二月三十一日止年度則約為人民幣14,877,000元。

Distribution and selling costs rose to approximately RMB276,949,000 for the year ended 31 December 2014 from approximately RMB255,319,000 in last year. These expenses accounted for 46% of turnover in 2014, which represented a 10% decrease from 56% as compared with the corresponding period of last year. The distribution and selling costs increase approximately RMB21,630,000.

For the year ended 31 December 2014, administrative expenses increased to approximately RMB67,901,000 from approximately RMB37,347,000 last year.

LIQUIDITY AND FINANCIAL RESOURCES

The Group has maintained a sound financial position during this year. As at 31 December 2014, cash and bank balances of the Group amounted to RMB130,316,000 (2013: RMB70,359,000) with total borrowings of RMB8,830,000 (2013: RMB8,830,000) which were interest bearing at commercial rates and unsecured. As at 31 December 2014, the Group had total assets of RMB783,666,000 (2013: RMB650,123,000) which were financed by current liabilities of RMB151,239,000 (2013: RMB151,461,000), long term borrowings of RMB7,513,000 (2013: RMB8,148,000), deferred tax liabilities of RMB239,000 (2013: RMB338,000) and shareholders' equity of RMB606,317,000 (2013: RMB473,532,000).

GEARING RATIO

As at 31 December 2014, the Group had a net cash and cash equivalents of RMB130,316,000. As at 31 December 2014, the ratio of the total liabilities to the total assets of the Group was 23% (2013: 27%) which was calculated by dividing the Group's total liabilities of RMB177,349,000 (2013: RMB176,591,000) by the Group's total equity and liabilities of RMB783,666,000 (2013: RMB650,123,000). The Group's gearing ratio which derived from the total borrowings to total net assets was 1.5% (2013: 1.9%).

EMPLOYEES

The Group has a total of 550 full-time employees and has employed some temporary sales persons.

Remuneration is determined by reference to market conditions and the performance, qualifications and experience of individual employee. Discretionary bonuses based on individual performance will be paid to employees as recognition of and reward for their contribution. Other benefits include contributions to retirement scheme and medical scheme.

截至二零一四年十二月三十一日止年度，分銷及銷售開支由去年約人民幣255,319,000元增加至約人民幣276,949,000元。於二零一四年，該等開支佔營業額的百分比為46%，較去年同期之56%減少10%。分銷及銷售開支增加達約人民幣21,630,000元。

截至二零一四年十二月三十一日止年度，行政開支由去年約人民幣37,347,000元增加至約人民幣67,901,000元。

流動資金及財政來源

本集團於本年度維持穩健的財政狀況。於二零一四年十二月三十一日，本集團的現金及銀行結餘合共為人民幣130,316,000元(二零一三年：人民幣70,359,000元)，總貸款為人民幣8,830,000元(二零一三年：人民幣8,830,000元)。該等貸款以商業利率計息，並無抵押。於二零一四年十二月三十一日，本集團的資產總值為人民幣783,666,000元(二零一三年：人民幣650,123,000元)，資金來源為流動負債人民幣151,239,000元(二零一三年：人民幣151,461,000元)、長期貸款人民幣7,513,000元(二零一三年：人民幣8,148,000元)、遞延稅項負債人民幣239,000元(二零一三年：人民幣338,000元)及股東權益人民幣606,317,000元(二零一三年：人民幣473,532,000元)。

負債比率

於二零一四年十二月三十一日，本集團擁有現金及現金等值物人民幣130,316,000元。於二零一四年十二月三十一日，本集團負債總額相對於資產總值之比率為23%(二零一三年：27%)，該負債比率按本集團總負債人民幣177,349,000元(二零一三年：人民幣176,591,000元)除本集團總權益與總負債人民幣783,666,000元(二零一三年：人民幣650,123,000元)計算得出。本集團的資產負債比率(以借款總額相對於資產總淨值之比率計算)為1.5%(二零一三年：1.9%)。

僱員

本集團共僱用正式員工550人，並聘用若干臨時銷售人員。

薪酬乃參照市場條件以及個別僱員的表現、資歷及經驗而釐定。酌情花紅乃按個別僱員的表現支付予僱員，作為對他們的貢獻之認同及獎勵。其他福利包括退休計劃供款及醫療計劃。

SEGMENTAL INFORMATION

The Group has only one business segment which is the manufacture and distribution of biochemical medicines in the PRC. In 2014, turnover of the Group was generated entirely from sales in the PRC and all identifiable assets of the Group are located in the PRC. Accordingly, no business or geographical segmental analysis is prepared for the year.

CAPITAL STRUCTURE

The operations of the Group were financed mainly by shareholders' equity. The Group will continue to adopt its treasury policy of placing the Group's cash and cash equivalents in interest bearing deposits, and to fund operations with internal resources.

CHARGE OF ASSET

As at 31 December 2014 and 2013, the Group had no security over its assets.

FOREIGN EXCHANGE RISK

For the years ended 31 December 2014 and 2013, the Group mainly generated revenue and incurred costs in Renminbi. The directors consider the impact on foreign exchange exposure of the Group is minimal. Accordingly the Group did not employ any financial instruments for hedging purposes.

CONTINGENT LIABILITIES

As at 31 December 2014 and 2013, the Group had no material contingent liabilities.

PURCHASE, SALES OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the year.

分類資料

本集團只有一個業務分類，即於中國製造和分銷生化藥物。於二零一四年，本集團營業額全部來自中國之銷售，且本集團所有可識別資產均位於中國。因此，本年度並無編製業務或地區分類分析。

股本結構

本集團之營運主要由股權支付。本集團將繼續採納其財務政策，將本集團之現金及現金等值物存放於計息存款並以內部資源支付其營運所需資金。

資產抵押

於二零一四年及二零一三年十二月三十一日，本集團的資產並無抵押。

外匯風險

截至二零一四年及二零一三年十二月三十一日止年度，本集團之主要收益及成本乃以人民幣計算。董事認為，外匯風險對本集團之影響甚微。因此，本集團並無運用任何財務工具作對沖用途。

或然負債

於二零一四年及二零一三年十二月三十一日，本集團並無任何重大或然負債。

購買、出售或贖回上市證券

年內，本公司或其附屬公司概無購買、出售或贖回本公司任何上市證券。

DIRECTORS' AND SUPERVISORS' INTERESTS IN SHARES

At 31 December 2014, the interests and short positions of the Directors, supervisors and chief executives of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO") as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange (the "GEM Listing Rules") were as follows:

Long positions in shares

Director 董事	Type of Interests 權益類別	Capacity 身份	Number of Domestic Shares 內資股數目	Percentage of Domestic Shares 佔內資股百分比	Percentage of total registered Share Capital 佔總註冊股本 的百分比
Zhang Hong 張弘	Personal 個人	Beneficial owner 實益擁有人	101,937,000	26.29	18.19
Zhang Xiao Guang 張曉光	Personal 個人	Beneficial owner 實益擁有人	42,315,000	10.91	7.55
Wu Guo Wen 吳國文	Personal 個人	Beneficial owner 實益擁有人	900,000	0.232	0.161

Save as disclosed above, as at 31 December 2014, none of the Directors, supervisors and chief executives of the Company has any interests and short positions in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept under section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the GEM Listing Rules.

董事及監事於股份的權益

於二零一四年十二月三十一日，本公司董事、監事及主要行政人員於本公司及其任何相聯法團(定義見證券及期貨條例(「證券及期貨條例」)第XV部)的股份、相關股份及債券中擁有根據證券及期貨條例第352條，須列入該條所述登記冊的權益及淡倉，或根據聯交所創業板證券上市規則(「創業板上市規則」)第5.46條至5.67條所指董事買賣最低標準而須知會本公司及聯交所的權益及淡倉如下：

於股份的長倉

除上文所披露者外，於二零一四年十二月三十一日，本公司董事、監事及主要行政人員概無於本公司及其任何相聯法團(定義見證券及期貨條例第XV部)的股份、相關股份及債券中擁有根據證券及期貨條例第352條，須列入該條所述登記冊的權益及淡倉，或根據創業板上市規則第5.46條至5.67條所指董事買賣最低標準而須知會本公司及聯交所的權益及淡倉。

DIRECTORS' RIGHTS TO ACQUIRE SHARES

Saved as disclosed under the headings "Directors' and supervisors' interests in shares" above, at no time during the year were there any rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any director, supervisor and chief executive or their respective spouses or children under 18 years of age, or were any such rights exercised by them; or was the Company, its holding company, or any of its subsidiaries a party to any arrangement to enable the directors, supervisors and chief executives to acquire such rights in any other body corporate.

董事購入股份的權利

除上文「董事及監事於股份的權益」一段所披露者外，各董事、監事及主要行政人員或彼等各自的配偶或十八歲以下子女概無獲授或行使任何透過購入本公司股份或債券而獲取利益之權利；而本公司、其控股公司或其任何附屬公司亦無訂立任何安排，讓董事、監事及主要行政人員可於任何其他法團購入該等權利。

INTERESTS DISCLOSEABLE UNDER THE SFO AND SUBSTANTIAL SHAREHOLDERS

As at 31 December 2014, the following persons (other than the Directors, supervisors and chief executives of the Company) had interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO.

根據證券及期貨條例須予披露的權益及主要股東

於二零一四年十二月三十一日，按照本公司根據證券及期貨條例第336條置存的股東名冊顯示，以下人士(本公司董事、監事及主要行政人員除外)於本公司股份及相關股份中持有權益及淡倉。

Long positions in Domestic shares

於內資股的長倉

Name of shareholder	Capacity/ Nature of Interest	Number of Domestic Shares	Percentage of Domestic Shares	Percentage of total registered Share Capital 佔總註冊股本 的百分比
股東名稱	身份／權益性質	內資股數目	佔內資股百分比	
Huinan County SAB (Note) 輝南縣財源投資有限責任公司(附註)	Beneficial owner 實益擁有人	81,975,000	21.14	14.63

Note: Apart from the equity interest in the Company, Huinan County SAB does not have any direct or indirect interest in the Company, including representatives in the Board of Directors.

附註：除佔本公司的股本權益外，輝南縣財源投資有限責任公司並無擁有本公司的任何直接或間接權益，包括在董事會內的代表。

Long positions in H shares

於H股的長倉

Name of shareholder	Capacity	Number of H Shares	Percentage of H Shares	Percentage of total registered Share Capital 佔總註冊股本 的百分比
股東名稱	身份	H股數目	佔H股百分比	
Chen Jingwei 陳京偉	Beneficial owner 實益擁有人	29,520,000	17.11%	5.269%
Shen Qianzhen 沈茜珍	Beneficial owner 實益擁有人	13,996,000	8.11%	2.498%

COMPETING INTEREST

None of the Directors, the management shareholders, the significant shareholders or the substantial shareholders (as defined in the GEM Listing Rules) of the Company had any interest in a business, which competes or may compete with the business of the Group.

PRE-EMPTIVE RIGHT

There are no provisions for pre-emptive rights under the article of association of the Company or the laws of the PRC, being the jurisdiction in which the Company was established, which would oblige the Company to offer new shares on a pro rata basis to existing shareholders.

CONNECTED TRANSACTIONS

During the year, the Group had no material related party transactions, which constituted connected transactions under the GEM Listing Rules.

COMPLIANCE WITH CORPORATE GOVERNANCE PRACTICES

The Company is committed to achieve high standards of corporate governance to safeguard the interest of its shareholders and enhance its corporate value. Throughout the year ended 31 December 2014 and up to the date of this annual report, the Company has complied with the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules, subject to the deviations disclosed hereof.

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Under the code provision A.2.1, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Zhang Hong assumes the role of both the chairman and the chief executive officer of the Company. The Board is of the view that this has not compromised accountability and independent decision making for the following reasons:

- the Audit Committee composes exclusively of Independent Non-executive Directors;
- the Independent Directors have free and direct access to the Company's external auditors and independent professional advice when considered necessary.

Mr. Zhang Hong, the chairman, is a substantial shareholder of the Company and has considerable industry experience. He is motivated to contribute to the growth and profitability of the Group. The Board is of the view that it is in the best interests of the Group to have an executive chairman so that the Board can have the benefit of a chairman who is knowledgeable about the business of the Group and is most capable to guide discussions and brief the Board in a timely manner on pertinent issues and developments to facilitate open dialogue between the Board and the management.

競爭權益

本公司各董事、管理層股東、高持股量股東或主要股東(定義見創業板上市規則)概無於對本集團業務構成或可能構成競爭的任何業務中擁有任何權益。

優先購股權

本公司之公司章程或中國法律(即本公司註冊成立之司法權區)並無有關優先購股權之規定,並無要求本公司須按比例向現有股東發售新股。

關連交易

於本年度內,本集團並無根據創業板上市規則構成關連交易之重大關連人士交易。

遵守企業管治常規

本公司致力於達致高標準的企業管治,以保障其股東權益及提升其企業價值。截至二零一四年十二月三十一日止整個年度及直至本年報刊發日期,本公司已遵守創業板上市規則附錄15所載企業管治守則所載的守則條文,惟以下披露之偏離者除外。

主席及行政總裁

根據守則條文A.2.1條規定,主席及行政總裁的角色應各自獨立,不應由同一人士所擔任。張弘先生現同時擔任本公司之主席及行政總裁。董事認為,此情況並未影響其問責及作出獨立決定,原因如下:

- 審核委員會僅由獨立非執行董事組成;
- 獨立董事可於認為有需要時隨時和直接尋求本公司外聘核數師意見及獨立專業意見。

主席張弘先生現為本公司主要股東且具備資深行業經驗。彼受推動為本集團之增長及盈利能力作出貢獻。董事會認為,擁有一位執行主席乃符合本集團之最佳利益,因為藉此董事會可受惠於獲得一位對本集團業務具深厚認識,並有能力於有關事宜及發展適時引導董事會作出討論和向董事會進行簡報,藉以促進董事會與管理層之間的公開交流。

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted a code of conduct regarding securities transactions by directors on terms no less than the required standard of dealings as set out in rules 5.48 to 5.67 of the GEM Listing Rules. The Company has also made specific enquiry of all Directors and the Company was not aware of any non-compliance with the required standard of dealings and its code of conduct regarding securities transactions by Directors throughout the year ended 31 December 2014.

BOARD OF DIRECTORS AND BOARD MEETINGS

The Directors of the Company during the year and up to the date of this report were:

Executive Directors

Mr. Zhang Hong (*Chairman*)
Mr. Zhang Xiao Guang
Mr. Tian Xin Guo (resigned with effect from 2 September 2014)
Mr. Chen Qi Ming (resigned with effect from 2 September 2014)
Mr. Wu Guo Wen
Mr. Zhao Bao Gang

Independent Non-Executive Directors

Mr. Gao Yong Cai (appointed with effect from 20 May 2014)
Mr. Shen Yu Xiang (resigned with effect from 27 November 2014)
Mr. Xue Chang Qing (resigned with effect from 20 May 2014)
Mr. Yan Li Jin (resigned with effect from 27 November 2014)

As at the date of this report, the Board comprised five Directors, four of whom are Executive Directors, one of whom is INED of the Company.

AUDIT COMMITTEE

The Audit Committee was established in 2001 and currently comprises one member, Mr. Gao Yong Cai. All of them is INEDs. The chairman of the Audit Committee is Mr. Gao Yong Cai. The Board considers that each Audit Committee has broad commercial experience and there is a suitable mix of expertise in business, legal, accounting and financial management in the Audit Committee.

董事進行證券交易的標準守則

本公司已就董事進行證券交易採納操守準則，條款不寬於創業板上市規則第5.48至5.67條所載董事進行證券交易的標準守則。本公司經向全體董事作出特定查詢後，於截至二零一四年十二月三十一日止年度全年，本公司並不知悉任何不遵守證券交易規定準則和有關董事進行證券交易操守準則之情況。

董事會及董事會會議

年內及截至本報告日期，本公司董事有：

執行董事

張弘先生(主席)
張曉光先生
田新國先生(自二零一四年九月二日起辭任)
陳啟明先生(自二零一四年九月二日起辭任)
吳國文先生
趙寶剛先生

獨立非執行董事

高永才先生(自二零一四年五月二十日起獲委任)
沈玉祥先生(自二零一四年十一月二十七日起辭任)
薛長清先生(自二零一四年五月二十日起辭任)
鄒禮金先生(自二零一四年十一月二十七日起辭任)

於本報告日期，董事會由五名董事組成，其中四名為本公司之執行董事，一名為本公司之獨立非執行董事。

審核委員會

審核委員會成立於二零零一年，目前由高永才先生一名成員組成。彼等均為獨立非執行董事。審核委員會主席為高永才先生。董事會認為各審核委員會成員均具有廣泛的商業經驗，審核委員會內適當地融合了商業、法律、會計及財務管理等方面的專業知識。

None of the members of the Audit Committee has any personal financial interests, conflicts of interests arising from cross-directorships or day-to-day involvement in the running of the business. The Audit Committee oversees the financial reporting process and the adequacy and effectiveness of the Company's system of internal control. During the year, the Audit Committee carried out their own independent review of the interim and annual financial statements and financial reports and statements included in circulars of the Company published during the year. And with the assistance of the internal audit department, which reports directly to the committee, the Audit Committee completed its review of the adequacy and effectiveness of the Company's systems of internal control and reported its findings and recommendations to the Board.

STATUS OF OUTSTANDING APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS, AUDIT AND REMUNERATION COMMITTEE MEMBERS

At 27 November, 2014, Mr. Shen Yu Xiang and Mr. Yan Li Jin have resigned as an independent non-executive director ("INED") and audit and remuneration committee members of the Company and ceased to be a member of the Committee. Pursuant to the rules 5.28 of the GEM Listing Rules, the audit and remuneration Committee must comprise a minimum of three members and the audit Committee is now composed of only one INED, namely Mr. Gao Yong Cai.

The Company requires more time than expected to identify suitable candidates as new INED, audit and remuneration committee members. The Group has identified suitable candidates, but there are formalities and procedures which the Group cannot finalize at that moment. In the meantime, the Company has only one INED and audit committee member and two remuneration committee members and thus is temporarily unable to strictly comply with Rules 5.05(1) and 5.28 of the GEM Listing Rules requiring the Company to retain at all times three INEDs and a minimum of three members to comprise the audit committee, and with Rules of 5.05A requiring the Company to appoint INEDs representing at least one-third of the board, and with Rules of 5.34 requiring the Company to establish a remuneration committee chaired by an independent non-executive director and comprising a majority of independent non-executive directors. Also, the Company has breached the requirements of Listing Rules of 5.06 and 5.33 which require the Company to fill up the outstanding position within three months from the date of failing to meet these requirements.

The Board expects that the new appointment could be finalized as soon as possible and that the Company would be able to fully comply with Rules 5.05(1), 5.05A, 5.28 and 5.34 of the GEM Listing Rules as soon as possible. Further announcement will be made by the Company once the new appointment is confirmed in due course.

審核委員會概無成員擁有任何個人權益、自跨董事身份產生利益衝突或參與日常本公司業務經營。審核委員會監督財務報告程序及本公司內部監控系統之充足性和有效性。年內，審核委員會曾獨立審閱年內刊發載於本公司通函之中期及年度財務報表及財務報告及報表。審核委員會亦於直接向委員報告之內部審核部門協助下，完成審核本公司內部監控系統之充足性和有效性，並向董事會報告其調查結果及建議。

獨立非執行董事及審核與薪酬委員會成員尚待委任情況

於二零一四年十一月二十七日，沈玉祥先生及鄒禮金先生辭任本公司之獨立非執行董事（「獨立非執行董事」），並不再成為審核委員會、審核與薪酬與委員會成員之成員。根據創業板上市規則第5.28條，審核與薪酬委員會須最少由三名成員組成，而審核委員會現時由一名獨立非執行董事組成，即高永才先生。

本公司需要多於預期之時間物色新任獨立非執行董事及審核與薪酬委員會成員人選。本集團已確定適合人選，惟無法當即完成所須手續及程序。目前本公司只有一名獨立非執行董事及審核委員會成員及兩名薪酬委員會成員，故暫時未能嚴格遵守創業板上市規則第5.05(1)及5.28條要求本公司於所有時間保持三名獨立非執行董事及審核委員會最少由三名成員組成之規定，及5.05A條要求所委任的獨立非執行董事必須佔董事會成員人數至少三分之一，及5.34條要求設立薪酬委員會，並由獨立非執行董事出任主席，大部分成員須為獨立非執行董事。此外，本公司亦已違反上市規則第5.06條及5.33條要求本公司由未能符合該等規定當日起計之三個月內填補空缺之規定。

董事會預期新任命將儘快完成，以便本公司儘早完全符合創業板上市規則第5.05(1)、5.05A、5.28及5.34條之規定。待新委任確定後本公司將於適當時候另行發表公佈。

AUDITORS

A resolution will be submitted to Annual General Meeting of the Company to re-appoint the auditors, Reanda Lau & Au Yeung (HK) CPA Limited.

By order of the Board

Zhang Hong

Chairman

Jilin Province, the PRC
30 March 2015

As at the date of this announcement, the Board comprises four executive directors, being Zhang Hong, Zhang Xiao Guang, Wu Guo Wen and Zhao Bao Gang and one independent non-executive director, being Gao Yong Cai.

This announcement will remain on the "Latest Company Announcements" page on the GEM Website at www.hkgem.com for at least 7 days from the date of its posting.

核數師

本公司將於週年股東大會上提呈決議案以續聘利安達劉歐陽(香港)會計師事務所有限公司為本公司核數師。

承董事會命

張弘

主席

中國吉林省
二零一五年三月三十日

於本公佈日期，董事會成員包括四名執行董事，即張弘、張曉光、吳國文、趙寶剛；以及一名獨立非執行董事，即高永才組成。

本公佈將由其刊載日期起計至少七天於創業板網站 www.hkgem.com「最新公司公告」一欄刊登。